Comparative Pharmacology
Head-to-head clinical analysis: ALBENZA versus PIPERAZINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENZA versus PIPERAZINE CITRATE.
ALBENZA vs PIPERAZINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
None Documented
None Documented
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic